O
PTCT icon

OrbiMed’s PTC Therapeutics PTCT Stock Holding History

OrbiMed’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-50,000
Closed -$2.41M – 140
2015
Q2 		$2.41M Buy
+50,000
New +$2.92M 0.02% 126

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

OrbiMed's PTCT Position: Q1 2026 in Review

OrbiMed increased its PTC Therapeutics (PTCT) stake by 112% in Q1 2026, buying an estimated $1.83M and bringing the position to 49,100 shares worth $3.35M. The position accounts for 0.07% of the portfolio, ranked #102.

OrbiMed first reported a position in PTCT in Q1 2014 and has held it in 12 quarters since. The position peaked at $94M in Q2 2019. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • OrbiMed held 49,100 shares of PTC Therapeutics worth $3.35M as of Q1 2026.
  • OrbiMed bought 25,900 PTC Therapeutics shares in Q1 2026, an estimated $1.83M.
  • PTC Therapeutics made up 0.07% of OrbiMed's portfolio in Q1 2026, its #102 holding.
  • OrbiMed first reported a position in PTC Therapeutics in Q1 2014 and has held it in 12 quarters since.
  • OrbiMed's PTC Therapeutics position peaked at $94M in Q2 2019.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.